1. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., Торопцова Н.В., Алексеева Л.И., Бирюкова Е.В., Гребенникова Т.А., Дзеранова Л.К., Древаль А.В., Загородний Н.В., Ильин А.В., Крюкова И.В., Лесняк О.М., Мамедова Е.О., Никитинская О.А., Пигарова Е.А., Родионова С.С., Скрипникова И.А., Тарбаева Н.В., Фарба Л.Я., Цориев Т.Т., Чернова Т.О., Юренева С.В., Якушевская О.В., Дедов И.И. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы Эндокринологии. 2017; 63(6): 392 - 426.

2. Camacho P.M., Petak S.M., Binkley N., Clarke B.L., Harris S.T., Hurley D.L., Kleerekoper M., Lewiecki E.M., Miller P.D., Narula H.S., Pessah-Pollack R., Tangpricha V., Wimalawansa S.J., Watts N.B. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2016 // Endocrine Practice. - 2016. - Vol. 22. - P. 1 - 42.

3. on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis J.A., Cooper C., Rizzoli R., Reginster J.-Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women // Osteoporosis International. - 2019. - Vol. 30. - No. 1. - P. 3 - 44.

4. Raman-Wilms L. Book Review: Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis // Annals of Pharmacotherapy. - 1999. - Vol. 33. - Book Review. - No. 12. - P. 1377 - 1378.

5. Kanis J.A., Diseases W.H.O.C. for M.B. Assessment of Osteoporosis at the Primary Health Care Level: WHO Scientific Group Technical Report. - WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, 2008.

6. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis // The American Journal of Medicine. - 1993. - Vol. 94. - Consensus development conference. - No. 6. - P. 646 - 650.

7. Михайлов Е.Е., Беневоленская Л.И. Руководство по остеопорозу. М.: БИНОМ. Лаборатория знаний; 2003.

8. Lesnyak O.M. Аудит состояния проблемы остеопороза в странах Восточной Европы и Центральной Азии 2010 // Остеопороз и остеопатии. - 2011. - Vol. 14. - No. 2. - P. 3 - 6.

9. Дедов И.И., Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я. Остеопороз - от редкого симптома эндокринных болезней до безмолвной эпидемии XX-XXI века. Проблемы Эндокринологии. 2011; 57(1): 35 - 45. https://doi.org/10.14341/probl201157135-45.

10. Ершова О.Б., Белова К.Ю., Белов М.В., Ганерт О.А., Гладкова Е.Н., Ходырев В.Н., Лесняк О.М., Давтян В.Г., Пилюкова Р.И., Романова М.А., Синицина О. С Эпидемиология переломов проксимального отдела бедренной кости у городского населения Российской Федерации: результаты многоцентрового исследования. Форум остеопороза, 23 - 25 сентября, 2012; Санкт-Петербург. Материалы научно-практической конференции "Остеопороз - важнейшая мультидисциплинарная проблема здравоохранения XXI века"; 23 - 27.

11. Меньшикова Л.В., Храмцова Н.А., Ершова О.Б. Ближайшие и отдаленные исходы переломов проксимального отдела бедра у лиц пожилого возраста и их медико-социальные последствия (по данным многоцентрового исследования). Остеопороз и остеопатии. 2002; 1: 8-11.

12. Добровольская О.В., Торопцова Н.В., Лесняк О.М. Экономические аспекты осложненного остеопороза: стоимость лечения в течение первого года после перелома. Современная ревматология. 2016; 10 (3): 29-34.

13. Бахтиярова С.А., Бортник С.Б., Лесняк О.М., Кузнецова Н.Л. Сравнительная оценка социальных последствий перелома проксимального отдела бедра и инфаркта миокарда у пациентов старшего возраста. Остеопороз и остеопатии. 2003; С.45.

14. Lesnyak O., Ershova O., Belova K., Gladkova E., Sinitsina O., Ganert O., Romanova M., Khodirev V., Johansson H., McCloskey E., Kanis J.A. Epidemiology of fracture in the Russian Federation and the development of a FRAX model // Archives of Osteoporosis. - 2012. - Vol. 7. - No. 1-2. - P. 67-73.

15. Cosman F., De Beur S.J., LeBoff M.S., Lewiecki E.M., Tanner B., Randall S., Lindsay R. Clinician's Guide to Prevention and Treatment of Osteoporosis // Osteoporosis International. - 2014. - Vol. 25. - No. 10. - P. 2359-2381.

16. Shepstone L., Lenaghan E., Cooper C., Clarke S., Fong-Soe-Khioe R., Mitchell N., et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial // The Lancet. - 2018. - Vol. 391. - Screening in the community to reduce fractures in older women (SCOOP). - No. 10122. - P. 741-747.

17. Turner D.A., Khioe R.F.S., Shepstone L., Lenaghan E., Cooper C., Gittoes N., Harvey N.C., Holland R., Howe A., McCloskey E., O'Neill T.W., Torgerson D., Fordham R., the SCOOP Study Team The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study // Journal of Bone and Mineral Research. - 2018. - Vol. 33. - The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK. - No. 5. - P. 845 - 851.

18. Hippisley-Cox J., Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores // BMJ. - 2009. - Vol. 339. - Predicting risk of osteoporotic fracture in men and women in England and Wales. - No. nov19 1. - P. b4229 - b4229.

19. Hoff M., Meyer H.E., Skurtveit S., Langhammer A., , Syversen U., Dhainaut A., Skovlund E., Abrahamsen B., Schei B. Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway // Osteoporosis International. - 2017. - Vol. 28. - Validation of FRAX and the impact of self-reported falls among elderly in a general population. - No. 10. - P. 2935 - 2944.

20. CaMos Research Group, Fraser L.-A., Langsetmo L., Berger C., Ioannidis G., Goltzman D., Adachi J.D., Papaioannou A., Josse R., Kovacs C.S., Olszynski W.P., Towheed T., Hanley D.A., Kaiser S.M., Prior J., Jamal S., Kreiger N., Brown J.P., Johansson H., Oden A., McCloskey E., Kanis J.A., Leslie W.D. Fracture prediction and calibration of a Canadian tool: a population-based report from CaMos // Osteoporosis International. - 2011. - Vol. 22. - Fracture prediction and calibration of a Canadian tool. - No. 3. - P. 829 - 837.

21. Leslie W.D., Lix L.M., Johansson H., Oden A., McCloskey E., Kanis J.A. Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration // Journal of Bone and Mineral Research. - 2010. - Vol. 25. - Independent clinical validation of a Canadian FRAX tool. - No. 11. - P. 2350-2358.

22. Jiang X., Gruner M., Tr mollieres F., Pluskiewicz W., Sornay-Rendu E., Adamczyk P., Schnatz P.F. Diagnostic accuracy of FRAX in predicting the 10-year risk of osteoporotic fractures using the USA treatment thresholds: A systematic review and meta-analysis // Bone. - 2017. - Vol. 99. - Diagnostic accuracy of FRAX in predicting the 10-year risk of osteoporotic fractures using the USA treatment thresholds. - P. 20-25.

23. Marques A., Ferreira R.J.O., Santos E., Loza E., Carmona L., Da Silva J.A.P. The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis // Annals of the Rheumatic Diseases. - 2015. - Vol. 74. - The accuracy of osteoporotic fracture risk prediction tools. - No. 11. - P. 1958-1967.

24. Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAXTM and the assessment of fracture probability in men and women from the UK // Osteoporosis International. - 2008. - Vol. 19. - No. 4. - P. 385-397.

25. Гладкова Е.Н., Никитинская О.А., Скрипникова И.А., Мягкова М.А., Баранова И.А., Белая Ж.Е., Белова К.Ю., Евстигнеева Л.П., Ершова О.Б., Заводовский Б.В., Косматова О.В., Оттева Э.Н., Полякова Ю.В., Сивордова Л.Е., Сулейманова А.К., Торопцова Н.В., Цориев Т.Т., Лесняк О.М. Разработка порога вмешательства для мужчин Российской Федерации при подсчете 10-летней вероятности переломов по FRAX: консенсус экспертов Российской ассоциации по остеопорозу. Научно-практическая ревматология. 2023; 61(3): 320-329.

26. Lindsay R. Risk of New Vertebral Fracture in the Year Following a Fracture // JAMA. - 2001. - Vol. 285. - No. 3. - P. 320.

27. Gehlbach S., Saag K.G., Adachi J.D., Hooven F.H., Flahive J., Boonen S., Chapurlat R.D., Compston J.E., Cooper C., , Greenspan S.L., LaCroix A.Z., Netelenbos J.C., Pfeilschifter J., Rossini M., Roux C., Sambrook P.N., Silverman S., Siris E.S., Watts N.B., Lindsay R. Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women // Journal of Bone and Mineral Research. - 2012. - Vol. 27. - Previous fractures at multiple sites increase the risk for subsequent fractures. - No. 3. - P. 645-653.

28. Edwards B.J., Bunta A.D., Simonelli C., Bolander M., Fitzpatrick L.A. Prior Fractures are Common in Patients with Subsequent Hip Fractures // Clinical Orthopaedics & Related Research. - 2007. - Vol. 461. - P. 226-230.

29. Ross P.D., Davis J.W., Epstein R.S., Wasnich R.D. Pre-Existing Fractures and Bone Mass Predict Vertebral Fracture Incidence in Women // Annals of Internal Medicine. - 1991. - Vol. 114. - No. 11. - P. 919-923.

30. Gallagher J.C., Genant H.K., Crans G.G., Vargas S.J., Krege J.H. Teriparatide Reduces the Fracture Risk Associated with Increasing Number and Severity of Osteoporotic Fractures // The Journal of Clinical Endocrinology & Metabolism. - 2005. - Vol. 90. - No. 3. - P. 1583-1587.

31. Marcus R., Wang O., Satterwhite J., Mitlak B. The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis // Journal of Bone and Mineral Research. - 2003. - Vol. 18. - No. 1. - P. 18-23.

32. Kanis J.A., Barton I.P., Johnell O. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture // Osteoporosis International. - 2005. - Vol. 16. - No. 5. - P. 475-482.

33. Johnell O., Kanis J.A., Black D.M., Balogh A., Poor G., Sarkar S., Zhou C., Pavo I. Associations Between Baseline Risk Factors and Vertebral Fracture Risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study // Journal of Bone and Mineral Research. - 2004. - Vol. 19. - No. 5. - P. 764-772.

34. Kanis J.A., Johansson H., Oden A., McCloskey E.V. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with // Osteoporosis International. - 2011. - Vol. 22. - No. 8. - P. 2347-2355.

35. Kanis J.A., Johnell O., De Laet C., Johansson H., Oden A., Delmas P., Eisman J., Fujiwara S., Garnero P., Kroger H., McCloskey E.V., Mellstrom D., Melton L.J., Pols H., Reeve J., Silman A., Tenenhouse A. A meta-analysis of previous fracture and subsequent fracture risk // Bone. - 2004. - Vol. 35. - No. 2. - P. 375-382.

36. Klotzbuecher C.M., Ross P.D., Landsman P.B., Abbott T.A., Berger M. Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis // Journal of Bone and Mineral Research. - 2000. - Vol. 15. - Patients with Prior Fractures Have an Increased Risk of Future Fractures. - No. 4. - P. 721-739.

37. Schousboe J.T., Ensrud K.E., Nyman J.A., Kane R.L., Melton L.J. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy // Osteoporosis International. - 2005. - Vol. 16. - No. 12. - P. 1883-1893.

38. Gallagher J.C., Sai A.J. Is screening for secondary causes of osteoporosis worthwhile? // Nature Reviews Endocrinology. - 2010. - Vol. 6. - No. 7. - P. 360-362.

39. Barzel US. Recommended testing in patients with low bone density. J Clin Endocrinol Metab 2003; 88(3): 1404-1405. doi: 10.1210/jc.2002-021951.

40. Tannenbaum C., Clark J., Schwartzman K., Wallenstein S., Lapinski R., Meier D., Luckey M. Yield of Laboratory Testing to Identify Secondary Contributors to Osteoporosis in Otherwise Healthy Women // The Journal of Clinical Endocrinology & Metabolism. - 2002. - Vol. 87. - No. 10. - P. 4431-4437.

41. , Peris P., Monegal A., Albaladejo C., , , De Osaba M.J., , Search for hidden secondary causes in postmenopausal women with osteoporosis // Menopause. - 2010. - Vol. 17. - No. 1. - P. 135-139.

42. Deutschmann H.A., Weger M., Weger W., Kotanko P., Deutschmann M.J., Skrabal F. Search for occult secondary osteoporosis: impact of identified possible risk factors on bone mineral density // Journal of Internal Medicine. - 2002. - Vol. 252. - Search for occult secondary osteoporosis. - No. 5. - P. 389-397.

43. Priemel M., Von Domarus C., Klatte T.O., Kessler S., Schlie J., Meier S., Proksch N., Pastor F., Netter C., Streichert T., , Amling M. Bone mineralization defects and vitamin D deficiency: Histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients // Journal of Bone and Mineral Research. - 2010. - Vol. 25. - Bone mineralization defects and vitamin D deficiency. - No. 2. - P. 305-312.

44. Eastell R., Barton I., Hannon R., Chines A., Garnero P., Delmas P. Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate // Journal of Bone and Mineral Research. - 2003. - Vol. 18. - No. 6. - P. 1051-1056.

45. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., Ross P.D. Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents // The Journal of Clinical Endocrinology & Metabolism. - 2002. - Vol. 87. - No. 4. - P. 1586-1592.

46. Bone H.G., Hosking D., Devogelaer J.-P., Tucci J.R., Emkey R.D., Tonino R.P., Rodriguez-Portales J.A., Downs R.W., Gupta J., Santora A.C., Liberman U.A. Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women // New England Journal of Medicine. - 2004. - Vol. 350. - No. 12. - P. 1189-1199.

47. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., Satterfield S., Wallace R.B., Bauer D.C., Palermo L., Wehren L.E., Lombardi A., Santora A.C., Cummings S.R., Flex Research Group F.T. Effects of Continuing or Stopping Alendronate After 5 Years of Treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A Randomized Trial // JAMA. - 2006. - Vol. 296. - Effects of Continuing or Stopping Alendronate After 5 Years of Treatment. - No. 24. - P. 2927.

48. Delmas PD., Eastell R., Garnero P., Seibel MJ., Stepan J., Committee of Scientific Advisors of the International Osteoporosis Foundation] The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000; 11 Suppl 6: 2-17. doi: 10.1007/s001980070002.

49. for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran S., Eastell R., , Foldes A.J., Garnero P., Griesmacher A., McClung M., Morris H.A., Silverman S., Trenti T., Wahl D.A., Cooper C., Kanis J.A. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards // Osteoporosis International. - 2011. - Vol. 22. - Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment. - No. 2. - P. 391-420.

50. IFCC-IOF Joint Working Group on Standardisation of Biochemical Markers of Bone Turnover, Johansson H., , Kanis J.A., McCloskey E.V., Morris H.A., Cooper C., Vasikaran S. A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture // Calcified Tissue International. - 2014. - Vol. 94. - No. 5. - P. 560-567.

51. Bauer D.C., Black D.M., Bouxsein M.L., Lui L.-Y., Cauley J.A., De Papp A.E., Grauer A., Khosla S., McCulloch C.E., Eastell R., for the Foundation for the National Institutes of Health (FNIH) Bone Quality Project Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression // Journal of Bone and Mineral Research. - 2018. - Vol. 33. - Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs. - No. 4. - P. 634-642.

52. Ravn P., Hosking D., Thompson D., Cizza G., Wasnich R.D., McClung M., Yates A.J., Bjarnason N.H., Christiansen C. Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study1 // The Journal of Clinical Endocrinology & Metabolism. - 1999. - Vol. 84. - No. 7. - P. 2363-2368.

53. Fink E., Cormier C., Steinmetz P., Kindermans C., Le Bouc Y., Souberbielle J.-C. Differences in the Capacity of Several Biochemical Bone Markers to Assess High Bone Turnover in Early Menopause and Response to Alendronate Therapy: // Osteoporosis International. - 2000. - Vol. 11. - Differences in the Capacity of Several Biochemical Bone Markers to Assess High Bone Turnover in Early Menopause and Response to Alendronate Therapy. - No. 4. - P. 295-303.

54. Bauer D.C., Black D.M., Garnero P., Hochberg M., Ott S., Orloff J., Thompson D.E., Ewing S.K., Delmas P.D., for the Fracture Intervention Trial Study Group Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial // Journal of Bone and Mineral Research. - 2004. - Vol. 19. - Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women. - No. 8. - P. 1250-1258.

55. For the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE), Delmas P.D., Recker R.R., Chesnut C.H., Skag A., Stakkestad J.A., Emkey R., Gilbride J., Schimmer R.C., Christiansen C. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study // Osteoporosis International. - 2004. - Vol. 15. - Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk. - No. 10. - P. 792-798.

56. Reginster J.-Y., Gieschke R. Clinical Utility of a Pharmacostatistical Model for Ibandronate in Postmenopausal Osteoporosis // Current Drug Metabolism. - 2006. - Vol. 7. - No. 7. - P. 827-836.

57. Krege J.H., Lane N.E., Harris J.M., Miller P.D. PINP as a biological response marker during teriparatide treatment for osteoporosis // Osteoporosis International. - 2014. - Vol. 25. - No. 9. - P. 2159-2171.

58. Imaz I., Zegarra P., , Rubio B., Alcazar R., Amate J.M. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis // Osteoporosis International. - 2010. - Vol. 21. - Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk. - No. 11. - P. 1943-1951.

59. Bergmann P., Body J.-J., Boonen S., Boutsen Y., Devogelaer J.-P., Goemaere S., Kaufman J.-M., Reginster J.-Y., Gangji V., Members of the Advisory Board on Bone Markers Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club // International Journal of Clinical Practice. - 2009. - Vol. 63. - Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis. - No. 1. - P. 19-26.

60. Burch J., Rice S., Yang H., Neilson A., Stirk L., Francis R., Holloway P., Selby P., Craig D. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups // Health Technology Assessment. - 2014. - Vol. 18. - Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment. - No. 11.

61. Dresner-Pollak R., Parker R.A., Poku M., Thompson J., Seibel M.J., Greenspan S.L. Biochemical Markers of Bone Turnover Reflect Femoral Bone Loss in Elderly Women // Calcified Tissue International. - 1996. - Vol. 59. - No. 5. - P. 328-333.

62. Dr. Ross P.D., Knowlton W. Rapid Bone Loss Is Associated with Increased Levels of Biochemical Markers // Journal of Bone and Mineral Research. - 1998. - Vol. 13. - No. 2. - P. 297-302.

63. Hansen M.A., Overgaard K., Riis B.J., Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. // BMJ. - 1991. - Vol. 303. - Role of peak bone mass and bone loss in postmenopausal osteoporosis. - No. 6808. - P. 961-964.

64. Garnero P., Sornay-Rendu E., Duboeuf F., Delmas P.D. Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years: The OFELY Study // Journal of Bone and Mineral Research. - 1999. - Vol. 14. - Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years. - No. 9. - P. 1614-1621.

65. Tian A., Ma J., Feng K., Liu Z., Chen L., Jia H., Ma X. Reference markers of bone turnover for prediction of fracture: a meta-analysis // Journal of Orthopaedic Surgery and Research. - 2019. - Vol. 14. - Reference markers of bone turnover for prediction of fracture. - No. 1. - P. 68.

66. Schousboe J.T., Bauer D.C., Nyman J.A., Kane R.L., Melton L.J., Ensrud K.E. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy // Osteoporosis International. - 2007. - Vol. 18. - No. 2. - P. 201-210.

67. Boonen S., Body J.-J., Boutsen Y., Devogelaer J.-P., Goemaere S., Kaufman J.-M., Rozenberg S., Reginster J.-Y. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club // Osteoporosis International. - 2005. - Vol. 16. - Evidence-based guidelines for the treatment of postmenopausal osteoporosis. - No. 3. - P. 239-254.

68. McNabb B.L., Vittinghoff E., Schwartz A.V., Eastell R., Bauer D.C., Ensrud K., Rosenberg E., Santora A., Barrett-Connor E., Black D.M. BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate // Journal of Bone and Mineral Research. - 2013. - Vol. 28. - No. 6. - P. 1319-1327.

69. Bauer D.C., Schwartz A., Palermo L., Cauley J., Hochberg M., Santora A., Cummings S.R., Black D.M. Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy: The FLEX Study // JAMA Internal Medicine. - 2014. - Vol. 174. - Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy. - No. 7. - P. 1126.

70. Cosman F., Cauley J.A., Eastell R., Boonen S., Palermo L., Reid I.R., Cummings S.R., Black D.M. Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment? // The Journal of Clinical Endocrinology & Metabolism. - 2014. - Vol. 99. - Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid. - No. 12. - P. 4546-4554.

71. Bauer D.C., Garnero P., Hochberg M.C., Santora A., Delmas P., Ewing S.K., Black D.M. Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate: The Fracture Intervention Trial // Journal of Bone and Mineral Research. - 2006. - Vol. 21. - Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate. - No. 2. - P. 292-299.

72. Seibel M.J., Naganathan V., Barton I., Grauer A. Relationship Between Pretreatment Bone Resorption and Vertebral Fracture Incidence in Postmenopausal Osteoporotic Women Treated With Risedronate // Journal of Bone and Mineral Research. - 2004. - Vol. 19. - No. 2. - P. 323-329.

73. Yamamoto T., Tsujimoto M., Hamaya E., Sowa H. Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide administered subcutaneously in Japanese patients with osteoporosis // Journal of Bone and Mineral Metabolism. - 2013. - Vol. 31. - No. 2. - P. 199-205.

74. Kanis JA., Melton LJ., Christiansen C., Johnston CC., Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 2009; 9(8): 1137-1141. doi: 10.1002/jbmr.5650090802.

75. Nevitt M.C., Ettinger B., Black D.M., Stone K., Jamal S.A., Ensrud K., Segal M., Genant H.K., Cummings S.R. The Association of Radiographically Detected Vertebral Fractures with Back Pain and Function: A Prospective Study // Annals of Internal Medicine. - 1998. - Vol. 128. - The Association of Radiographically Detected Vertebral Fractures with Back Pain and Function. - No. 10. - P. 793-800.

76. Fink H.A., Litwack-Harrison S., Ensrud K.E., Shen J., Schousboe J.T., Cawthon P.M., Cauley J.A., Lane N.E., Taylor B.C., Barrett-Connor E., Kado D.M., Cummings S.R., Marshall L.M., for the Osteoporotic Fractures in Men (MrOS) Study Group Association of Incident, Clinically Undiagnosed Radiographic Vertebral Fractures With Follow-Up Back Pain Symptoms in Older Men: the Osteoporotic Fractures in Men (MrOS) Study // Journal of Bone and Mineral Research. - 2017. - Vol. 32. - Association of Incident, Clinically Undiagnosed Radiographic Vertebral Fractures With Follow-Up Back Pain Symptoms in Older Men. - No. 11. - P. 2263-2268.

77. Yamamoto M., Yamaguchi T., Yamauchi M., Kaji H., Sugimoto T. Diabetic Patients Have an Increased Risk of Vertebral Fractures Independent of BMD or Diabetic Complications // Journal of Bone and Mineral Research. - 2009. - Vol. 24. - No. 4. - P. 702-709.

78. Siminoski K., Jiang G., Adachi J.D., Hanley D.A., Cline G., Ioannidis G., Hodsman A., Josse R.G., Kendler D., Olszynski W.P., Ste. Marie L.-G., Eastell R. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures // Osteoporosis International. - 2005. - Vol. 16. - No. 4. - P. 403-410.

79. Leslie W.D., Schousboe J.T., Morin S.N., Martineau P., Lix L.M., Johansson H., McCloskey E.V., Harvey N.C., Kanis J.A. Measured height loss predicts incident clinical fractures independently from FRAX: a registry-based cohort study // Osteoporosis International. - 2020. - Vol. 31. - Measured height loss predicts incident clinical fractures independently from FRAX. - No. 6. - P. 1079-1087.

80. Van Staa T.P., Leufkens H.G.M., Abenhaim L., Zhang B., Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses // Rheumatology. - 2000. - Vol. 39. - Oral corticosteroids and fracture risk. - No. 12. - P. 1383-1389.

81. Byberg L., Gedeborg R., Cars T., , Berglund L., Kilander L., Melhus H., K. Prediction of fracture risk in men: A cohort study // Journal of Bone and Mineral Research. - 2012. - Vol. 27. - Prediction of fracture risk in men. - No. 4. - P. 797-807.

82. Dede A.D., Tournis S., Dontas I., Trovas G. Type 2 diabetes mellitus and fracture risk // Metabolism. - 2014. - Vol. 63. - No. 12. - P. 1480-1490.

83. Xu W., Perera S., Medich D., Fiorito G., Wagner J., Berger L.K., Greenspan S.L. Height loss, vertebral fractures, and the misclassification of osteoporosis // Bone. - 2011. - Vol. 48. - No. 2. - P. 307-311.

84. Kamimura M., Nakamura Y., Sugino N., Uchiyama S., Komatsu M., Ikegami S., Kato H., Taguchi A. Associations of self-reported height loss and kyphosis with vertebral fractures in Japanese women 60 years and older: a cross-sectional survey // Scientific Reports. - 2016. - Vol. 6. - Associations of self-reported height loss and kyphosis with vertebral fractures in Japanese women 60 years and older. - No. 1. - P. 29199.

85. Mikula A.L., Hetzel S.J., Binkley N., Anderson P.A. Validity of height loss as a predictor for prevalent vertebral fractures, low bone mineral density, and vitamin D deficiency // Osteoporosis International. - 2017. - Vol. 28. - No. 5. - P. 1659-1665.

86. Genant HK., Wu CY., van Kuijk C., Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 2009; 8(9): 1137-1148. doi: 10.1002/jbmr.5650080915.

87. Genant H.K., Jergas M. Assessment of prevalent and incident vertebral fractures in osteoporosis research // Osteoporosis International. - 2003. - Vol. 14. - No. S3. - P. 43-55.

88. Kazawa N. T2WI MRI and MRI-MDCT correlations of the osteoporotic vertebral compressive fractures // European Journal of Radiology. - 2012. - Vol. 81. - No. 7. - P. 1630-1636.

89. Baum T., Karampinos D., Liebl H., Rummeny E., Waldt S., Bauer J. High-Resolution Bone Imaging for Osteoporosis Diagnostics and Therapy Monitoring Using Clinical MDCT and MRI // Current Medicinal Chemistry. - 2013. - Vol. 20. - No. 38. - P. 4844-4852.

90. Петряйкин А.В., Белая Ж.Е., Киселева А.Н., Артюкова З.Р., Беляев М.Г., Кондратенко В.А. и др. Технология искусственного интеллекта для распознавания компрессионных переломов позвонков с помощью модели морфометрического анализа, основанной на сверточных нейронных сетях. Проблемы Эндокринологии. 2020;66(5):48-60.

91. Smets J., Shevroja E., , Leslie W.D., Hans D. Machine Learning Solutions for Osteoporosis-A Review // Journal of Bone and Mineral Research. - 2020. - Vol. 36. - No. 5. - P. 833-851.

92. Zakharov A., Pisov M., Bukharaev A., Petraikin A., Morozov S., Gombolevskiy V., Belyaev M. Interpretable vertebral fracture quantification via anchor-free landmarks localization // Medical Image Analysis. - 2023. - Vol. 83. - P. 102646.

93. Petraikin A.V., Pickhardt P.J., Belyaev M.G., Belaya Z.E., Pisov M.E., Bukharaev A.N., Zakharov A.A., Kudryavtsev N.D., Bobrovskaya T.M., Semenov D.S., Akhmad E.S., Artyukova Z.R., Abuladze L.R., Nizovtsova L.A., Blokhin I.A., Vladzymyrskyy A.V., Vasilev Y.A. Opportunistic screening for osteoporosis using artificial intelligence-based morphometric analysis of chest computed tomography images: a retrospective multicenter study in Russia leveraging the COVID-19 pandemic // Asian Spine Journal. - 2025. - Opportunistic screening for osteoporosis using artificial intelligence-based morphometric analysis of chest computed tomography images.

94. Jiang G., Eastell R., Barrington N.A., Ferrar L. Comparison of methods for the visual identification of prevalent vertebral fracture in osteoporosis // Osteoporosis International. - 2004. - Vol. 15. - No. 11. - P. 887-896.

95. Grigoryan M., Guermazi A., Roemer F.W., Delmas P.D., Genant H.K. Recognizing and reporting osteoporotic vertebral fractures // European Spine Journal. - 2003. - Vol. 12. - No. 0. - P. S104-S112.

96. Adams JE, Lenchik L, Roux C, Genant H (2010) Vertebral fracture initiative, Part II, radiological assessment of vertebral fracture. http://www.iofbonehealthorg/what-we-do/training-andeducation/educational-slide-kits/vertebral-fracture-teachingprogram.

97. Burns J.E., Yao J., Summers R.M. Vertebral Body Compression Fractures and Bone Density: Automated Detection and Classification on CT Images // Radiology. - 2017. - Vol. 284. - Vertebral Body Compression Fractures and Bone Density. - No. 3. - P. 788-797.

98. Papadakis A.E., Karantanas A.H., Papadokostakis G., Petinellis E., Damilakis J. Can abdominal multi-detector CT diagnose spinal osteoporosis? // European Radiology. - 2009. - Vol. 19. - No. 1. - P. 172-176.

99. Papadakis A.E., Karantanas A.H., Papadokostakis G., Damilakis J. Assessment of the morpho-densitometric parameters of the lumbar pedicles in osteoporotic and control women undergoing routine abdominal MDCT examinations // Journal of Bone and Mineral Metabolism. - 2011. - Vol. 29. - No. 3. - P. 352-358.

100. Baum T., Grande Garcia E., Burgkart R., Gordijenko O., Liebl H., Jungmann P.M., Gruber M., Zahel T., Rummeny E.J., Waldt S., Bauer J.S. Osteoporosis imaging: effects of bone preservation on MDCT-based trabecular bone microstructure parameters and finite element models // BMC Medical Imaging. - 2015. - Vol. 15. - Osteoporosis imaging. - No. 1. - P. 22.

101. Damilakis J., Adams J.E., Guglielmi G., Link T.M. Radiation exposure in X-ray-based imaging techniques used in osteoporosis // European Radiology. - 2010. - Vol. 20. - No. 11. - P. 2707-2714.

102. The Advisory Board of the National Osteoporosis Guideline Group, Kanis J.A., Harvey N.C., Cooper C., Johansson H., , McCloskey E.V. A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation // Archives of Osteoporosis. - 2016. - Vol. 11. - A systematic review of intervention thresholds based on FRAX. - No. 1. - P. 25.

103. Merlijn T., Swart KMA., van der Horst HE., Netelenbos JC., Elders PJM. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int 2020; 31(2): 251-257. doi: 10.1007/s00198-019-05226-w.

104. Rubin K.H., Rothmann M.J., Holmberg T., , , Barkmann R., , Hermann A.P., Bech M., Gram J., Brixen K. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study // Osteoporosis International. - 2018. - Vol. 29. - Effectiveness of a two-step population-based osteoporosis screening program using FRAX. - No. 3. - P. 567-578.

105. Kanis J.A., McCloskey E.V., Johansson H., Strom O., Borgstrom F., Oden A., National Osteoporosis Guideline Group Case finding for the management of osteoporosis with FRAX(R)-assessment and intervention thresholds for the UK // Osteoporosis International. - 2008. - Vol. 19. - No. 10. - P. 1395-1408.

106. Kanis J.A., Johnell O., De Laet C., Jonsson B., Oden A., Ogelsby A.K. International Variations in Hip Fracture Probabilities: Implications for Risk Assessment // Journal of Bone and Mineral Research. - 2002. - Vol. 17. - International Variations in Hip Fracture Probabilities. - No. 7. - P. 1237-1244.

107. De Laet C.E.D.H., Van Hout B.A., Burger H., Weel A.E.A.M., Hofman A., Pols H.A.P. Hip Fracture Prediction in Elderly Men and Women: Validation in the Rotterdam Study // Journal of Bone and Mineral Research. - 1998. - Vol. 13. - Hip Fracture Prediction in Elderly Men and Women. - No. 10. - P. 1587-1593.

108. Kanis J.A., Delmas P., Burckhardt P., Cooper C., Torgerson D. Guidelines for diagnosis and management of osteoporosis // Osteoporosis International. - 1997. - Vol. 7. - No. 4. - P. 390-406.

109. Kanis J.A., McCloskey E.V., Johansson H., Cooper C., Rizzoli R., Reginster J.-Y., on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) European guidance for the diagnosis and management of osteoporosis in postmenopausal women // Osteoporosis International. - 2013. - Vol. 24. - No. 1. - P. 23-57.

110. Joint IOF-ECTS GIO Guidelines Working Group, Lekamwasam S., Adachi J.D., Agnusdei D., Bilezikian J., Boonen S., , Cooper C., Diez Perez A., Eastell R., Hofbauer L.C., Kanis J.A., Langdahl B.L., Lesnyak O., Lorenc R., McCloskey E., Messina O.D., Napoli N., Obermayer-Pietsch B., Ralston S.H., Sambrook P.N., Silverman S., Sosa M., Stepan J., Suppan G., Wahl D.A., Compston J.E. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis // Osteoporosis International. - 2012. - Vol. 23. - No. 9. - P. 2257-2276.

111. Алексеева Л.И., Баранова И.А., Белова К.Ю., и др. Клинические рекомендации по профилактике и ведению больных с остеопорозом. - Ярославль: Литера; 2012. - С. 23.

112. Никитинская О.А., Торопцова Н.В. Оценка риска переломов с использованием модели FRAX(R) (ретроспективное десятилетнее исследование) Альманах клинической медицины. 2014;43:50-55.

113. National Osteoporosis Foundation (NOF) and International Society for Clinical Densitometry (ISCD). Recommendations to DXA Manufacturers for FRAX(R) Implementation. Available http://www.nof.org/files/nof/public/content/resource/862/files/392.pdf. Accessed January 28, 2013.

114. Kanis J.A., Johansson H., Oden A., McCloskey E.V. Guidance for the adjustment of FRAX according to the dose of glucocorticoids // Osteoporosis International. - 2011. - Vol. 22. - No. 3. - P. 809-816.

115. Kanis J.A., Johansson H., Oden A., Johnell O., De Laet C., Melton L.J., Tenenhouse A., Reeve J., Silman A.J., Pols H.A., Eisman J.A., McCloskey E.V., Mellstrom D. A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk // Journal of Bone and Mineral Research. - 2004. - Vol. 19. - No. 6. - P. 893-899.

116. Staa T.P.V., Staa T.P.V., Staa T.P.V., Leufkens H.G.M., Cooper C. The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis // Osteoporosis International. - 2002. - Vol. 13. - The Epidemiology of Corticosteroid-Induced Osteoporosis. - No. 10. - P. 777-787.

117. Ferrari S.L., Abrahamsen B., Napoli N., Akesson K., Chandran M., Eastell R., El-Hajj Fuleihan G., Josse R., Kendler D.L., Kraenzlin M., Suzuki A., Pierroz D.D., Schwartz A.V., Leslie W.D., on behalf of the Bone and Diabetes Working Group of IOF, Ferrari S.L., Abrahamsen B., Akesson K., Ardawi M.S.M., Chandran M., Cooper C., Eastell R., El-Hajj Fuleihan G., Josse R., Kendler D.L., Kraenzlin M., Leslie W.D., Mithal A., Napoli N., Suzuki A., Schwartz A.V. Diagnosis and management of bone fragility in diabetes: an emerging challenge // Osteoporosis International. - 2018. - Vol. 29. - Diagnosis and management of bone fragility in diabetes. - No. 12. - P. 2585-2596.

118. Leslie W.D., Johansson H., McCloskey E.V., Harvey N.C., Kanis J.A., Hans D. Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry // Journal of Bone and Mineral Research. - 2018. - Vol. 33. - Comparison of Methods for Improving Fracture Risk Assessment in Diabetes. - No. 11. - P. 1923-1930.

119. Baleanu F., Bergmann P., Hambye A.S., Dekelver C., Iconaru L., Cappelle S.I., Moreau M., Paesmans M., Karmali R., Body J. Assessment of bone quality with trabecular bone score in type 2 diabetes mellitus: A study from the FRISBEE cohort // International Journal of Clinical Practice. - 2019. - Vol. 73. - Assessment of bone quality with trabecular bone score in type 2 diabetes mellitus. - No. 5. - P. e13347.

120. Johansson H., Oden A., Johnell O., Jonsson B., De Laet C., Oglesby A., McCloskey E.V., Kayan K., Jalava T., Kanis J.A. Optimization of BMD Measurements to Identify High Risk Groups for Treatment-A Test Analysis // Journal of Bone and Mineral Research. - 2004. - Vol. 19. - No. 6. - P. 906-913.

121. Tosteson A.N.A., Melton L.J., Dawson-Hughes B., Baim S., Favus M.J., Khosla S., Lindsay R.L. Cost-effective osteoporosis treatment thresholds: the United States perspective // Osteoporosis International. - 2008. - Vol. 19. - Cost-effective osteoporosis treatment thresholds. - No. 4. - P. 437-447.

122. for the Manitoba Bone Density Program, Leslie W.D., Morin S., Lix L.M., Johansson H., Oden A., McCloskey E., Kanis J.A. Fracture risk assessment without bone density measurement in routine clinical practice // Osteoporosis International. - 2012. - Vol. 23. - No. 1. - P. 75-85.

123. for the Manitoba Bone Density Program, Leslie W.D., Majumdar S.R., Lix L.M., Johansson H., Oden A., McCloskey E., Kanis J.A. High fracture probability with FRAX(R) usually indicates densitometric osteoporosis: implications for clinical practice // Osteoporosis International. - 2012. - Vol. 23. - High fracture probability with FRAX(R) usually indicates densitometric osteoporosis. - No. 1. - P. 391-397.

124. Kanis J.A., Oden A., Johnell O., Johansson H., De Laet C., Brown J., Burckhardt P., Cooper C., Christiansen C., Cummings S., Eisman J.A., Fujiwara S., , Goltzman D., Hans D., Krieg M.-A., La Croix A., McCloskey E., Mellstrom D., Melton L.J., Pols H., Reeve J., Sanders K., Schott A.-M., Silman A., Torgerson D., Van Staa T., Watts N.B., Yoshimura N. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women // Osteoporosis International. - 2007. - Vol. 18. - No. 8. - P. 1033-1046.

125. Kyriakos G., Vidal-Casariego A., , , Ballesteros-Pomar M.D., I. Impact of the NOGG and NOF Guidelines on the Indication of Bone Mineral Density in Routine Clinical Practice // Journal of Clinical Densitometry. - 2015. - Vol. 18. - No. 4. - P. 533-538.

126. Johansson H., Kanis J.A., Oden A., Johnell O., McCloskey E. BMD, clinical risk factors and their combination for hip fracture prevention // Osteoporosis International. - 2009. - Vol. 20. - No. 10. - P. 1675-1682.

127. Johansson H., Kanis J.A., Oden A., Compston J., McCloskey E. A comparison of case-finding strategies in the UK for the management of hip fractures // Osteoporosis International. - 2012. - Vol. 23. - No. 3. - P. 907-915.

128. Kanis J.A., Adams J., , Cooper C., , Preedy D., Selby P., Compston J. The cost-effectiveness of alendronate in the management of osteoporosis // Bone. - 2008. - Vol. 42. - No. 1. - P. 4-15.

129. Cummings S.R., Karpf D.B., Harris F., Genant H.K., Ensrud K., LaCroix A.Z., Black D.M. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs // The American Journal of Medicine. - 2002. - Vol. 112. - No. 4. - P. 281-289.

130. Chen P., Miller P.D., Delmas P.D., Misurski D.A., Krege J.H. Change in Lumbar Spine BMD and Vertebral Fracture Risk Reduction in Teriparatide-Treated Postmenopausal Women With Osteoporosis // Journal of Bone and Mineral Research. - 2006. - Vol. 21. - No. 11. - P. 1785-1790.

131. Management of postmenopausal osteoporosis: position statement of The North American Menopause Society: // Menopause. - 2002. - Management of postmenopausal osteoporosis. - P. 84-101.

132. Leib E.S., Lewiecki E.M., Binkley N., Hamdy R.C. Official Positions of the International Society for Clinical Densitometry // Journal of Clinical Densitometry. - 2004. - Vol. 7. - No. 1. - P. 1-5.

133. Shepherd J.A., Blake G.M. T-Scores and Z-Scores // Journal of Clinical Densitometry. - 2007. - Vol. 10. - No. 4. - P. 349-350.

134. Watts N.B., Leslie W.D., Foldes A.J., Miller P.D. 2013 International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases // Journal of Clinical Densitometry. - 2013. - Vol. 16. - 2013 International Society for Clinical Densitometry Position Development Conference. - No. 4. - P. 472-481.

135. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1-129.

136. Kelly TL. Bone mineral density reference databases for American men and women. J Bone Miner Res 1990, 5(Suppl 2):S249.

137. Hanson J. Standardization of Femur BMD // Journal of Bone and Mineral Research. - 1997. - Vol. 12. - No. 8. - P. 1316-1317.

138. Kanis J.A., McCloskey E.V., Johansson H., Oden A., Melton L.J., Khaltaev N. A reference standard for the description of osteoporosis // Bone. - 2008. - Vol. 42. - No. 3. - P. 467-475.

139. Nelson HD., Haney EM., Chou R., Dana T., Fu R., Bougatsos C. Screening for Osteoporosis: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010.

140. Dr. Melton J.L. Perspectives: How many women have osteoporosis now? // Journal of Bone and Mineral Research. - 1995. - Vol. 10. - Perspectives. - No. 2. - P. 175-177.

141. Bonnick S. Bone Densitometry in Clinical Practice. Humana Press Inc. 2004:411. n.d.

142. McCloskey E.V., , Harvey N.C., Leslie W.D., Hans D., Johansson H., Barkmann R., Boutroy S., Brown J., Chapurlat R., Elders P.J., Fujita Y., , Goltzman D., Iki M., Karlsson M., Kindmark A., Kotowicz M., Kurumatani N., Kwok T., Lamy O., Leung J., Lippuner K., , Lorentzon M., , Merlijn T., Oei L., Ohlsson C., Pasco J.A., Rivadeneira F., Rosengren B., Sornay-Rendu E., Szulc P., Tamaki J., Kanis J.A. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX // Journal of Bone and Mineral Research. - 2016. - Vol. 31. - No. 5. - P. 940-948.

143. the Scientific Committee of the GRIO (Groupe de Recherche et d'Information sur les ), Bousson V., Bergot C., Sutter B., Levitz P., Cortet B. Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects // Osteoporosis International. - 2012. - Vol. 23. - Trabecular bone score (TBS). - No. 5. - P. 1489-1501.

144. International Society for Clinical Densitometry. 2013 Official Positions - Adult. http://www.iscd.org/ official-positions/2013-iscd-official-positions-adult.

145. 2019 ISCD Official Positions - Adult - International Society for Clinical Densitometry (ISCD) https://iscd.org/learn/official-positions/.

146. Петряйкин А.В., Скрипникова И.А. Количественная компьютерная томография, современные данные. Обзор. Медицинская визуализация. 2021;25(4):134-146.

147. Петряйкин А.В., Сморчкова А.К., Кудрявцев Н.Д., Сергунова К.А., Артюкова З.Р., Абуладзе Л.Р., Яссин Л.Р., Петряйкин Ф.А., Лобанов М.Н., Николаев А.Е., Хоружая А.Н., Семенов Д.С., Низовцова Л.А., Владзимирский А.В., Морозов С.П. Сравнение двух методик асинхронной КТ денситометрии. Медицинская визуализация. 2020; 24 (4): 108-118. https://doi.org/10.24835/1607-0763-2020-4-108-118.

148. Петряйкин А.В., Торопцова Н.В., Никитинская О.А., Кузнецов С.Ю., Низовцова Л.А., Ахмад Е.С., и др. Применение асинхронной количественной компьютерной томографии для оппортунистического скрининга остеопороза. Научно-практическая ревматология. 2022; 60(3):360-368.

149. ACR-SPR-SSR Practice parameter for the performance of quantitative computed tomography (QCT) bone mineral density Revised 2023 (Resolution 15)* https://www.acr.org/-/media/ACR/Files/Practice-Parameters/QCT.pdf.

150. Engelke K., Lang T., Khosla S., Qin L., Zysset P., Leslie W.D., Shepherd J.A., Schousboe J.T. Clinical Use of Quantitative Computed Tomography (QCT) of the Hip in the Management of Osteoporosis in Adults: the 2015 ISCD Official Positions-Part I // Journal of Clinical Densitometry. - 2015. - Vol. 18. - Clinical Use of Quantitative Computed Tomography (QCT) of the Hip in the Management of Osteoporosis in Adults. - No. 3. - P. 338-358.

151. Ziemlewicz T.J., Maciejewski A., Binkley N., Brett A.D., Brown J.K., Pickhardt P.J. Opportunistic Quantitative CT Bone Mineral Density Measurement at the Proximal Femur Using Routine Contrast-Enhanced Scans: Direct Comparison With DXA in 355 Adults // Journal of Bone and Mineral Research. - 2016. - Vol. 31. - Opportunistic Quantitative CT Bone Mineral Density Measurement at the Proximal Femur Using Routine Contrast-Enhanced Scans. - No. 10. - P. 1835-1840.

152. Conversano F., Franchini R., Greco A., Soloperto G., , Casciaro E., Aventaggiato M., Renna M.D., Pisani P., Di Paola M., Grimaldi A., Quarta L., Quarta E., Muratore M., Laugier P., Casciaro S. A Novel Ultrasound Methodology for Estimating Spine Mineral Density // Ultrasound in Medicine & Biology. - 2015. - Vol. 41. - No. 1. - P. 281-300.

153. Cortet B., Dennison E., Diez-Perez A., Locquet M., Muratore M., , Ovejero Crespo D., Quarta E., Brandi M.L. Radiofrequency Echographic Multi Spectrometry (REMS) for the diagnosis of osteoporosis in a European multicenter clinical context // Bone. - 2021. - Vol. 143. - P. 115786.

154. Di Paola M., Gatti D., Viapiana O., Cianferotti L., Cavalli L., Caffarelli C., Conversano F., Quarta E., Pisani P., Girasole G., Giusti A., Manfredini M., Arioli G., Matucci-Cerinic M., Bianchi G., Nuti R., Gonnelli S., Brandi M.L., Muratore M., Rossini M. Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck // Osteoporosis International. - 2019. - Vol. 30. - No. 2. - P. 391-402.

155. Pisani P., Conversano F., Muratore M., Adami G., Brandi M.L., Caffarelli C., Casciaro E., Di Paola M., Franchini R., Gatti D., Gonnelli S., Guglielmi G., Lombardi F.A., Natale A., Testini V., Casciaro S. Fragility Score: a REMS-based indicator for the prediction of incident fragility fractures at 5 years // Aging Clinical and Experimental Research. - 2023. - Fragility Score.

156. Camacho P.M., Petak S.M., Binkley N., Diab D.L., Eldeiry L.S., Farooki A., Harris S.T., Hurley D.L., Kelly J., Lewiecki E.M., Pessah-Pollack R., McClung M., Wimalawansa S.J., Watts N.B. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update // Endocrine Practice. - 2020. - Vol. 26. - P. 1-46.

157. Gregson C.L., Compston J.E. New national osteoporosis guidance-implications for geriatricians // Age and Ageing. - 2022. - Vol. 51. - No. 4. - P. afac044.

158. Choong D.S., Tan N.C., Koh Y.L.E., Leong C.K., Sankari U., Koh K.H. Osteoporosis management by primary care physicians in Singapore: a survey on osteoporosis guidelines utilisation and barriers to care // Archives of Osteoporosis. - 2023. - Vol. 18. - Osteoporosis management by primary care physicians in Singapore. - No. 1. - P. 72.

159. Choong D.S., Tan N.C., Koh Y.L.E., Leong C.K., Sankari U., Koh K.H. Correction to: Osteoporosis management by primary care physicians in Singapore: a survey on osteoporosis guidelines utilisation and barriers to care // Archives of Osteoporosis. - 2023. - Vol. 18. - Correction to. - No. 1. - P. 84.

160. Belaya Z., Rozhinskaya L., Dedov I., Drapkina O., Fadeev V., Golounina O., Lesnyak O., Mamedova E., Melnichenko G., Petraikin A., Rodionova S., Skripnikova I., Tkacheva O., Toroptsova N., Yureneva S., Kanis J.A. A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis // Osteoporosis International. - 2023. - Vol. 34. - No. 3. - P. 429-447.

161. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Ensrud K.E. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures // The Lancet. - 1996. - Vol. 348. - No. 9041. - P. 1535-1541.

162. Cummings S.R. Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention Trial // JAMA. - 1998. - Vol. 280. - No. 24. - P. 2077.

163. Orwoll E., Ettinger M., Weiss S., Miller P., Kendler D., Graham J., Adami S., Weber K., Lorenc R., Pietschmann P., Vandormael K., Lombardi A. Alendronate for the Treatment of Osteoporosis in Men // New England Journal of Medicine. - 2000. - Vol. 343. - No. 9. - P. 604-610.

164. Saag K.G., Emkey R., Schnitzer T.J., Brown J.P., Hawkins F., Goemaere S., Thamsborg G., Liberman U.A., Delmas P.D., Malice M.-P., Czachur M., Daifotis A.G. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: // Obstetrical & Gynecological Survey. - 1999. - Vol. 54. - Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. - No. 1. - P. 39-40.

165. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., Adami S., Fogelman I., Diamond T., Eastell R., Meunier P.J., Wasnich R.D., Greenwald M., Kaufman J.-M., Chesnut C.H., Reginster J.-Y. Effect of Risedronate on the Risk of Hip Fracture in Elderly Women // New England Journal of Medicine. - 2001. - Vol. 344. - No. 5. - P. 333-340.

166. Boonen S., Orwoll E.S., Wenderoth D., Stoner K.J., Eusebio R., Delmas P.D. Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study // Journal of Bone and Mineral Research. - 2009. - Vol. 24. - Once-Weekly Risedronate in Men With Osteoporosis. - No. 4. - P. 719-725.

167. Eastell R., Devogelaer J.-P., Peel N.F.A., Chines A.A., Bax D.E., Sacco-Gibson N., Nagant De Deuxchaisnes C., Russell R.G.G. Prevention of Bone Loss with Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients // Osteoporosis International. - 2000. - Vol. 11. - No. 4. - P. 331-337.

168. Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., Felsenberg D., Huss H., Gilbride J., Schimmer R.C., Delmas P.D., for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE) Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis // Journal of Bone and Mineral Research. - 2004. - Vol. 19. - No. 8. - P. 1241-1249.

169. Miller P.D., Mcclung M.R., Macovei L., Stakkestad J.A., Luckey M., Bonvoisin B., Reginster J.-Y., Recker R.R., Hughes C., Lewiecki E.M., Felsenberg D., Delmas P.D., Kendler D.L., Bolognese M.A., Mairon N., Cooper C. Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study // Journal of Bone and Mineral Research. - 2005. - Vol. 20. - Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis. - No. 8. - P. 1315-1322.

170. Recker R.R., Ste-Marie L.-G., Langdahl B., Czerwinski E., Bonvoisin B., Masanauskaite D., Rowell L., Felsenberg D. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: The DIVA study // Bone. - 2010. - Vol. 46. - Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis. - No. 3. - P. 660-665.

171. Harris S.T., Blumentals W.A., Miller P.D. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies // Current Medical Research and Opinion. - 2008. - Vol. 24. - Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis. - No. 1. - P. 237-245.

172. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C., Man Z., Mautalen C., Mesenbrink P., Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T.F., Sellmeyer D., Eriksen E.F., Cummings S.R. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis // New England Journal of Medicine. - 2007. - Vol. 356. - No. 18. - P. 1809-1822.

173. Boonen S., Reginster J.-Y., Kaufman J.-M., Lippuner K., Zanchetta J., Langdahl B., Rizzoli R., Lipschitz S., Dimai H.P., Witvrouw R., Eriksen E., Brixen K., Russo L., Claessens F., Papanastasiou P., Antunez O., Su G., Bucci-Rechtweg C., Hruska J., Incera E., Vanderschueren D., Orwoll E. Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis // New England Journal of Medicine. - 2012. - Vol. 367. - No. 18. - P. 1714-1723.

174. Reid D.M., Devogelaer J.-P., Saag K., Roux C., Lau C.-S., Reginster J.-Y., Papanastasiou P., Ferreira A., Hartl F., Fashola T., Mesenbrink P., Sambrook P.N. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial // The Lancet. - 2009. - Vol. 373. - Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON). - No. 9671. - P. 1253-1263.

175. Hakala M., , Valleala H., Hienonen-Kempas T., Lehtonen-Veromaa M., Heikkinen J., Tuomiranta T., Hannonen P., Paimela L., for the ONCE trial group Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial // Scandinavian Journal of Rheumatology. - 2012. - Vol. 41. - Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases. - No. 4. - P. 260-266.

176. Ringe J.D., Dorst A., Faber H., Ibach K., Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study // Osteoporosis International. - 2003. - Vol. 14. - Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis. - No. 10. - P. 801-807.

177. Orwoll E.S., Binkley N.C., Lewiecki E.M., Gruntmanis U., Fries M.A., Dasic G. Efficacy and safety of monthly ibandronate in men with low bone density // Bone. - 2010. - Vol. 46. - No. 4. - P. 970-976.

178. Lyles K.W., , Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., Hyldstrup L., Recknor C., Nordsletten L., Moore K.A., Lavecchia C., Zhang J., Mesenbrink P., Hodgson P.K., Abrams K., Orloff J.J., Horowitz Z., Eriksen E.F., Boonen S. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture // New England Journal of Medicine. - 2007. - Vol. 357. - No. 18. - P. 1799-1809.

179. McClung M., Miller P., Recknor C., Mesenbrink P., Bucci-Rechtweg C., Benhamou C.-L. Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass: A Randomized Controlled Trial // Obstetrics & Gynecology. - 2009. - Vol. 114. - Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass. - No. 5. - P. 999-1007.

180. Reid I.R., Horne A.M., Mihov B., Stewart A., Garratt E., Wong S., Wiessing K.R., Bolland M.J., Bastin S., Gamble G.D. Fracture Prevention with Zoledronate in Older Women with Osteopenia // New England Journal of Medicine. - 2018. - Vol. 379. - No. 25. - P. 2407-2416.

181. Cummings S.R., Martin J.S., McClung M.R., Siris E.S., Eastell R., Reid I.R., Delmas P., Zoog H.B., Austin M., Wang A., Kutilek S., Adami S., Zanchetta J., Libanati C., Siddhanti S., Christiansen C. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis // New England Journal of Medicine. - 2009. - Vol. 361. - No. 8. - P. 756-765.

182. Langdahl B.L., , Ho P.-R., Chapurlat R., Czerwinski E., Kendler D.L., Reginster J.-Y., Kivitz A., Lewiecki E.M., Miller P.D., Bolognese M.A., McClung M.R., Bone H.G., , Abrahamsen B., Gruntmanis U., Yang Y.-C., Wagman R.B., Mirza F., Siddhanti S., Orwoll E. A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial // The Journal of Clinical Endocrinology & Metabolism. - 2015. - Vol. 100. - A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density. - No. 4. - P. 1335-1342.

183. Orwoll E., , Langdahl B.L., Chapurlat R., Czerwinski E., Kendler D.L., Reginster J.-Y., Kivitz A., Lewiecki E.M., Miller P.D., Bolognese M.A., McClung M.R., Bone H.G., , Abrahamsen B., Gruntmanis U., Yang Y.-C., Wagman R.B., Siddhanti S., Grauer A., Hall J.W., Boonen S. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density // The Journal of Clinical Endocrinology & Metabolism. - 2012. - Vol. 97. - No. 9. - P. 3161-3169.

184. Saag K.G., Pannacciulli N., Geusens P., Adachi J.D., Messina O.D., Morales-Torres J., Emkey R., Butler P.W., Yin X., Lems W.F. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial // Arthritis & Rheumatology. - 2019. - Vol. 71. - Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis. - No. 7. - P. 1174-1184.

185. Gnant M., Pfeiler G., Dubsky P.C., Hubalek M., Greil R., Jakesz R., Wette V., Balic M., Haslbauer F., Melbinger E., Bjelic-Radisic V., Artner-Matuschek S., Fitzal F., Marth C., Sevelda P., Mlineritsch B., Steger G.G., Manfreda D., Exner R., Egle D., Bergh J., Kainberger F., Talbot S., Warner D., Fesl C., Singer C.F. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial // The Lancet. - 2015. - Vol. 386. - Adjuvant denosumab in breast cancer (ABCSG-18). - No. 9992. - P. 433-443.

186. Smith M.R., Egerdie B., Toriz N.H., Feldman R., Tammela T.L.J., Saad F., Heracek J., Szwedowski M., Ke C., Kupic A., Leder B.Z., Goessl C. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer // New England Journal of Medicine. - 2009. - Vol. 361. - No. 8. - P. 745-755.

187. Amiche M.A., Albaum J.M., Tadrous M., Pechlivanoglou P., , Adachi J.D., Cadarette S.M. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis // Osteoporosis International. - 2016. - Vol. 27. - Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users. - No. 6. - P. 1989-1998.

188. Coskun Benlidayi I. Denosumab in the treatment of glucocorticoid-induced osteoporosis // Rheumatology International. - 2018. - Vol. 38. - No. 11. - P. 1975-1984.

189. Yanbeiy Z.A., Hansen K.E. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis // Drug Design, Development and Therapy. - 2019. - Vol. Volume 13. - Denosumab in the treatment of glucocorticoid-induced osteoporosis. - P. 2843-2852.

190. Yamaguchi Y., Morita T., Kumanogoh A. The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis // Rheumatology Advances in Practice. - 2020. - Vol. 4. - The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis. - No. 1. - P. rkaa008.

191. Mandema J.W., Zheng J., Libanati C., Perez Ruixo J.J. Time Course of Bone Mineral Density Changes With Denosumab Compared With Other Drugs in Postmenopausal Osteoporosis: A Dose-Response-Based Meta-Analysis // The Journal of Clinical Endocrinology & Metabolism. - 2014. - Vol. 99. - Time Course of Bone Mineral Density Changes With Denosumab Compared With Other Drugs in Postmenopausal Osteoporosis. - No. 10. - P. 3746-3755.

192. Miller P.D., Bolognese M.A., Lewiecki E.M., McClung M.R., Ding B., Austin M., Liu Y., San Martin J. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial // Bone. - 2008. - Vol. 43. - Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy. - No. 2. - P. 222-229.

193. Brown J.P., Prince R.L., Deal C., Recker R.R., Kiel D.P., De Gregorio L.H., Hadji P., Hofbauer L.C., , Wang H., Austin M., Wagman R.B., Newmark R., Libanati C., San Martin J., Bone H.G. Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial // Journal of Bone and Mineral Research. - 2009. - Vol. 24. - Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass. - No. 1. - P. 153-161.

194. Choi N.-K., Solomon D.H., Tsacogianis T.N., Landon J.E., Song H.J., Kim S.C. Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study // Journal of Bone and Mineral Research. - 2017. - Vol. 32. - Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis. - No. 3. - P. 611-617.

195. Kendler D.L., Roux C., Benhamou C.L., Brown J.P., Lillestol M., Siddhanti S., Man H.-S., Martin J.S., Bone H.G. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy // Journal of Bone and Mineral Research. - 2010. - Vol. 25. - No. 1. - P. 72-81.

196. Tsai J.N., Uihlein A.V., Burnett-Bowie S.-A.M., Neer R.M., Zhu Y., Derrico N., Lee H., Bouxsein M.L., Leder B.Z. Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study // Journal of Bone and Mineral Research. - 2015. - Vol. 30. - Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength. - No. 1. - P. 39-45.

197. Broadwell A., Chines A., Ebeling P.R., Franek E., Huang S., Smith S., Kendler D., Messina O., Miller P.D. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease // The Journal of Clinical Endocrinology & Metabolism. - 2021. - Vol. 106. - No. 2. - P. 397-409.

198. Meier C., Uebelhart B., Aubry-Rozier B., Birkhuser M., Bischoff-Ferrari H.A., Frey D., Kressig R.W., Lamy O., Lippuner K., Stute P., Suhm N., Ferrari S. Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO // Swiss Medical Weekly. - 2017. - Osteoporosis drug treatment.

199. Miller P.D., Pannacciulli N., Brown J.P., Czerwinski E., Nedergaard B.S., Bolognese M.A., Malouf J., Bone H.G., Reginster J.-Y., Singer A., Wang C., Wagman R.B., Cummings S.R. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates // The Journal of Clinical Endocrinology & Metabolism. - 2016. - Vol. 101. - No. 8. - P. 3163-3170.

200. McClung M.R. Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies // Current Osteoporosis Reports. - 2006. - Vol. 4. - Inhibition of RANKL as a treatment for osteoporosis. - No. 1. - P. 28-33.

201. Белая Ж.Е., Рожинская Л.Я. Новые направления в терапии остеопороза - применение моноклональных человеческих антител к RANKL (Деносумаб). Остеопороз и Остеопатии. 2011;2:19-22.

202. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.-Y., Hodsman A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., , Oefjord E.S., Marcinowska-Suchowierska E., Salmi J., Mulder H., Halse J., Sawicki A.Z., Mitlak B.H. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis // New England Journal of Medicine. - 2001. - Vol. 344. - No. 19. - P. 1434-1441.

203. Orwoll E., Scheele W., Paul S., Adami S., Syversen U., Diez-Perez A., Kaufman J.-M., Clancy A., Gaich G. The Effect of Teriparatide [Human Parathyroid Hormone (1-34)] Therapy on Bone Density in Men With Osteoporosis // Journal of Bone and Mineral Research. - 2003. - Vol. 18. - No. 1. - P. 9-17.

204. Saag K.G., Shane E., Boonen S., , Donley D.W., Taylor K.A., Dalsky G.P., Marcus R. Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis // New England Journal of Medicine. - 2007. - Vol. 357. - No. 20. - P. 2028-2039.

205. Saag K.G., Zanchetta J.R., Devogelaer J., Adler R.A., Eastell R., See K., Krege J.H., Krohn K., Warner M.R. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial // Arthritis & Rheumatism. - 2009. - Vol. 60. - Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis. - No. 11. - P. 3346-3355.

206. Liu C.-L., Lee H.-C., Chen C.-C., Cho D.-Y. Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis // Clinical and Investigative Medicine. - 2017. - Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis. - P. E146-E157.

207. Wang Y.-K., Qin S.-Q., Ma T., Song W., Jiang R.-Q., Guo J.-B., Li K., Zhang Y.-M. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials // Medicine. - 2017. - Vol. 96. - Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis. - No. 21. - P. e6970.

208. Kendler D.L., Marin F., Zerbini C.A.F., Russo L.A., Greenspan S.L., Zikan V., Bagur A., Malouf-Sierra J., Lakatos P., Fahrleitner-Pammer A., Lespessailles E., Minisola S., Body J.J., Geusens P., , P. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial // The Lancet. - 2018. - Vol. 391. - Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO). - No. 10117. - P. 230-240.

209. Body J.-J., Gaich G.A., Scheele W.H., Kulkarni P.M., Miller P.D., Peretz A., Dore R.K., Correa-Rotter R., Papaioannou A., Cumming D.C., Hodsman A.B. A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1-34)] with Alendronate in Postmenopausal Women with Osteoporosis // The Journal of Clinical Endocrinology & Metabolism. - 2002. - Vol. 87. - No. 10. - P. 4528-4535.

210. Hadji P., Zanchetta J.R., Russo L.A., Recknor C.P., Saag K.G., McKiernan F.E., Silverman S.L., Alam J., Burge R.T., Krege J.H., Lakshmanan M.L., Masica D.N., Mitlak B.H., Stock J.L. Effect of teriparatide compared with risedronate on back pain and incident vertebral fractures in postmenopausal women with osteoporotic vertebral fractures // Bone. - 2011. - Vol. 48. - P. S82-S83.

211. Miller PD., Shergy WJ., Body J-J., Chen P., Rohe ME., Krege JH. Long-term reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 2005; 32(8): 1556-1562.

212. Huang W., Nagao M., Yonemoto N., Guo S., Tanigawa T., Nishizaki Y. Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J) // Pharmacoepidemiology and Drug Safety. - 2023. - Vol. 32. - Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women. - No. 6. - P. 671-684.

213. Shoback D., Rosen C.J., Black D.M., Cheung A.M., Murad M.H., Eastell R. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update // The Journal of Clinical Endocrinology & Metabolism. - 2020. - Vol. 105. - Pharmacological Management of Osteoporosis in Postmenopausal Women. - No. 3. - P. 587-594.

214. Cosman F., Crittenden D.B., Adachi J.D., Binkley N., Czerwinski E., Ferrari S., Hofbauer L.C., Lau E., Lewiecki E.M., Miyauchi A., Zerbini C.A.F., Milmont C.E., Chen L., Maddox J., Meisner P.D., Libanati C., Grauer A. Romosozumab Treatment in Postmenopausal Women with Osteoporosis // New England Journal of Medicine. - 2016. - Vol. 375. - No. 16. - P. 1532-1543.

215. Saag K.G., Petersen J., Brandi M.L., Karaplis A.C., Lorentzon M., Thomas T., Maddox J., Fan M., Meisner P.D., Grauer A. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis // New England Journal of Medicine. - 2017. - Vol. 377. - No. 15. - P. 1417-1427.

216. Barrionuevo P., Kapoor E., Asi N., Alahdab F., Mohammed K., Benkhadra K., Almasri J., Farah W., Sarigianni M., Muthusamy K., Al Nofal A., Haydour Q., Wang Z., Murad M.H. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis // The Journal of Clinical Endocrinology & Metabolism. - 2019. - Vol. 104. - Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women. - No. 5. - P. 1623-1630.

217. Miller P.D., Adachi J.D., Albergaria B.-H., Cheung A.M., Chines A.A., Gielen E., Langdahl B.L., Miyauchi A., Oates M., Reid I.R., Santiago N.R., Vanderkelen M., Wang Z., Yu Z. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease // Journal of Bone and Mineral Research. - 2020. - Vol. 37. - No. 8. - P. 1437-1445.

218. Sato M., Inaba M., Yamada S., Emoto M., Ohno Y., Tsujimoto Y. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study // Journal of Bone and Mineral Metabolism. - 2021. - Vol. 39. - No. 6. - P. 1082-1090.

219. Lewiecki E.M., Blicharski T., Goemaere S., Lippuner K., Meisner P.D., Miller P.D., Miyauchi A., Maddox J., Chen L., Horlait S. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis // The Journal of Clinical Endocrinology & Metabolism. - 2018. - Vol. 103. - No. 9. - P. 3183-3193.

220. Langdahl B., Libanati C., Crittenden D.B., Bolognese M.A., Brown J.P., Daizadeh N.S., Dokoupilova E., Engelke K., Finkelstein J.S., Genant H.K., Goemaere S., Hyldstrup L., Jodar-Gimeno E., Keaveny T.M., Kendler D., Lakatos P., Maddox J., Malouf J., Massari F.E., Molina J.F. Superior Gains in Bone Mineral Density (BMD) and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide (TPTD) in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-label STRUCTURE Study // Bone Abstracts. - 2016. - Superior Gains in Bone Mineral Density (BMD) and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide (TPTD) in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy.

221. European Medicines Agency Press Office. EMEA recommends changes in the product Information for Protelos/ Osseor due to the risk of severe hypersensitivity reactions. EMEA/417458/2007.

222. European Medicines Agency: Recommendation to restrict the use of Protelos/Osseor (strontium ranelate) 25 April 2013 EMA/258269/2013.

223. European Medicines Agency: Protelos/Osseor (strontium ranelate) to remain available but with futher restrictions 15 April 2014 EMA 235924/2014. J Rheumatology. 2005;32:1556-1562.

224. O'Donnell S., Cranney A., Wells G., Adachi J., Reginster J. Strontium ranelate for preventing and treating postmenopausal osteoporosis. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2006. p. CD005326.pub2.

225. Adler R.A., El-Hajj Fuleihan G., Bauer D.C., Camacho P.M., Clarke B.L., Clines G.A., Compston J.E., Drake M.T., Edwards B.J., Favus M.J., Greenspan S.L., McKinney R., Pignolo R.J., Sellmeyer D.E. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research // Journal of Bone and Mineral Research. - 2016. - Vol. 31. - Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment. - No. 1. - P. 16-35.

226. Black D.M., Reid I.R., Boonen S., Bucci-Rechtweg C., Cauley J.A., Cosman F., Cummings S.R., Hue T.F., Lippuner K., Lakatos P., Leung P.C., Man Z., Martinez R.L.M., Tan M., Ruzycky M.E., Su G., Eastell R. The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) // Journal of Bone and Mineral Research. - 2012. - Vol. 27. - The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis. - No. 2. - P. 243-254.

227. Black D.M., Reid I.R., Cauley J.A., Cosman F., Leung P.C., Lakatos P., Lippuner K., Cummings S.R., Hue T.F., Mukhopadhyay A., Tan M., Aftring R.P., Eastell R. The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT) // Journal of Bone and Mineral Research. - 2015. - Vol. 30. - The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis. - No. 5. - P. 934-944.

228. On behalf of the IOF Epidemiology/Quality of Life Working Group, Dennison E.M., Cooper C., Kanis J.A., , Silverman S., McCloskey E., Abrahamsen B., Prieto-Alhambra D., Ferrari S. Fracture risk following intermission of osteoporosis therapy // Osteoporosis International. - 2019. - Vol. 30. - No. 9. - P. 1733-1743.

229. Bone H.G., Wagman R.B., Brandi M.L., Brown J.P., Chapurlat R., Cummings S.R., , Fahrleitner-Pammer A., Kendler D.L., Lippuner K., Reginster J.-Y., Roux C., Malouf J., Bradley M.N., Daizadeh N.S., Wang A., Dakin P., Pannacciulli N., Dempster D.W., Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension // The Lancet Diabetes & Endocrinology. - 2017. - Vol. 5. - 10 years of denosumab treatment in postmenopausal women with osteoporosis. - No. 7. - P. 513-523.

230. Bone H.G., Bolognese M.A., Yuen C.K., Kendler D.L., Miller P.D., Yang Y.-C., Grazette L., San Martin J., Gallagher J.C. Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass // The Journal of Clinical Endocrinology & Metabolism. - 2011. - Vol. 96. - No. 4. - P. 972-980.

231. Bone H.G., Chapurlat R., Brandi M.-L., Brown J.P., , Krieg M.-A., , Radominski S.C., Reginster J.-Y., Resch H., Ivorra J.A.R., Roux C., Vittinghoff E., Daizadeh N.S., Wang A., Bradley M.N., Franchimont N., Geller M.L., Wagman R.B., Cummings S.R., Papapoulos S. The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension // The Journal of Clinical Endocrinology & Metabolism. - 2013. - Vol. 98. - The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis. - No. 11. - P. 4483-4492.

232. Anagnostis P., Paschou S.A., Mintziori G., Ceausu I., Depypere H., Lambrinoudaki I., Mueck A., , Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., , Goulis D.G. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement // Maturitas. - 2017. - Vol. 101. - Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis. - P. 23-30.

233. Белая Ж.Е., Bilezikian J.P., Ершова О.Б., Лесняк О.М., Марченкова Л.А., Родионова С.С., Рожинская Л.Я., Торопцова Н.В., Юренева С.В. Возможности длительной терапии постменопаузального остеопороза: обзор результатов клинических исследований деносумаба и резолюция совета экспертов российской ассоциации по остеопорозу (РАОП). Остеопороз и остеопатии. 2018;21(1):17-22. https://doi.org/10.14341/osteo9760.

234. Brown J.P., Roux C., , Ho P.-R., Beck Jensen J.-E., Gilchrist N., Recknor C., Austin M., Wang A., Grauer A., Wagman R.B. Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial // Journal of Bone and Mineral Research. - 2013. - Vol. 28. - Discontinuation of denosumab and associated fracture incidence. - No. 4. - P. 746-752.

235. Popp A.W., Zysset P.K., Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics // Osteoporosis International. - 2016. - Vol. 27. - No. 5. - P. 1917-1921.

236. Tsourdi E., Langdahl B., Cohen-Solal M., Aubry-Rozier B., Eriksen E.F., , Obermayer-Pietsch B., Ralston S.H., Eastell R., Zillikens M.C. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS // Bone. - 2017. - Vol. 105. - Discontinuation of Denosumab therapy for osteoporosis. - P. 11-17.

237. Tsourdi E., Zillikens M.C., Meier C., Body J.-J., Gonzalez Rodriguez E., Anastasilakis A.D., Abrahamsen B., McCloskey E., Hofbauer L.C., , Obermayer-Pietsch B., Ralston S.H., Eastell R., Pepe J., Palermo A., Langdahl B. Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS // The Journal of Clinical Endocrinology & Metabolism. - 2021. - Vol. 106. - Fracture Risk and Management of Discontinuation of Denosumab Therapy. - No. 1. - P. 264-281.

238. , , Kaal A., Rejnmark L., Langdahl B. Hypercalcemia after discontinuation of long-term denosumab treatment // Osteoporosis International. - 2016. - Vol. 27. - No. 7. - P. 2383-2386.

239. Leder B.Z., Tsai J.N., Uihlein A.V., Wallace P.M., Lee H., Neer R.M., Burnett-Bowie S.-A.M. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial // The Lancet. - 2015. - Vol. 386. - Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study). - No. 9999. - P. 1147-1155.

240. Ebina K., Hashimoto J., Kashii M., Hirao M., Kaneshiro S., Noguchi T., Tsukamoto Y., Yoshikawa H. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis // Journal of Bone and Mineral Metabolism. - 2017. - Vol. 35. - No. 1. - P. 91-98.

241. Rittmaster R.S., Bolognese M., Ettinger M.P., Hanley D.A., Hodsman A.B., Kendler D.L., Rosen C.J. Enhancement of Bone Mass in Osteoporotic Women with Parathyroid Hormone followed by Alendronate1 // The Journal of Clinical Endocrinology & Metabolism. - 2000. - Vol. 85. - No. 6. - P. 2129-2134.

242. Burkard D., Beckett T., Kourtjian E., Messingschlager C., Sipahi R., Padley M., Stubbart J. Effects of bone remodeling agents following teriparatide treatment // Osteoporosis International. - 2018. - Vol. 29. - No. 6. - P. 1351-1357.

243. McClung M.R., Bolognese M.A., Brown J.P., Reginster J.-Y., Langdahl B.L., Maddox J., Shi Y., Rojeski M., Meisner P.D., Grauer A. A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab // Osteoporosis International. - 2020. - Vol. 31. - No. 11. - P. 2231-2241.

244. McClung M.R., Chines A., Brown J.P., Diez-Perez A., Resch H., Caminis J., Bolognese M.A., Goemaere S., Bone H.G., Zanchetta J.R., Maddox J., Rosen O., Bray S., Grauer A. OP0251 Effects of 2 Years of Treatment with Romosozumab Followed by 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density // Annals of the Rheumatic Diseases. - 2015. - Vol. 74. - P. 166-167.

245. Chiha M., Myers L.E., Ball C.A., Sinacore J.M., Camacho P.M. Long-Term Follow-up of patients on Drug Holiday from Bisphosphonates: Real-World Setting // Endocrine Practice. - 2013. - Vol. 19. - Long-Term Follow-up of patients on Drug Holiday from Bisphosphonates. - No. 6. - P. 989-994.

246. Gallagher A.M., Rietbrock S., Olson M., Van Staa T.P. Fracture Outcomes Related to Persistence and Compliance With Oral Bisphosphonates // Journal of Bone and Mineral Research. - 2008. - Vol. 23. - No. 10. - P. 1569-1575.

247. Pfeilschifter J., Steinebach I., Trampisch H.J., Rudolf H. Bisphosphonate drug holidays: Risk of fractures and mortality in a prospective cohort study // Bone. - 2020. - Vol. 138. - Bisphosphonate drug holidays. - P. 115431.

248. Wang M., Wu Y., Girgis C.M. Bisphosphonate Drug Holidays: Evidence From Clinical Trials and Real-World Studies // JBMR Plus. - 2022. - Vol. 6. - Bisphosphonate Drug Holidays. - No. 6. - P. e10629.

249. McClung M.R. Role of bone-forming agents in the management of osteoporosis // Aging Clinical and Experimental Research. - 2021. - Vol. 33. - No. 4. - P. 775-791.

250. for the IOF CSA Inadequate Responders Working Group, Diez-Perez A., Adachi J.D., Agnusdei D., Bilezikian J.P., Compston J.E., Cummings S.R., Eastell R., Eriksen E.F., Gonzalez-Macias J., Liberman U.A., Wahl D.A., Seeman E., Kanis J.A., Cooper C. Treatment failure in osteoporosis // Osteoporosis International. - 2012. - Vol. 23. - No. 12. - P. 2769-2774.

251. Shao H.-B., Yao Y.-M., Wang Z.-Y., Zhang Q.-F., Wei W. Effects of combined alendronate and alfacalcidol on prevention of fractures in osteoporosis patients: a network meta-analysis // International Journal of Clinical and Experimental Medicine. - 2015. - Vol. 8. - Effects of combined alendronate and alfacalcidol on prevention of fractures in osteoporosis patients. - No. 8. - P. 12935-12941.

252. Ringe J.D., Farahmand P., Schacht E., Rozehnal A. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial) // Rheumatology International. - 2007. - Vol. 27. - No. 5. - P. 425-434.

253. Harris S.T. Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled Trial // JAMA. - 1999. - Vol. 282. - No. 14. - P. 1344.

254. Reginster J.-Y., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., Lund B., Ethgen D., Pack S., Roumagnac I., Eastell R. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis // Osteoporosis International. - 2000. - Vol. 11. - No. 1. - P. 83-91.

255. Members of IOF Fracture Working Group, Silverman S.L., Kupperman E.S., Bukata S.V. Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group // Osteoporosis International. - 2016. - Vol. 27. - Fracture healing. - No. 7. - P. 2197-2206.

256. Oliver D., Connelly J.B., Victor C.R., Shaw F.E., Whitehead A., Genc Y., Vanoli A., Martin F.C., Gosney M.A. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses // BMJ. - 2007. - Vol. 334. - Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment. - No. 7584. - P. 82.

257. Schmidt K., , Vogt L., , Hildebrandt H.D., Fink M., Banzer W. einer auf Gangparameter und Alltagsfunktion bei postmenopausaler Osteoporose // Der . - 2012. - Vol. 41. - No. 3. - P. 200-205.

258. Pfeifer M., Begerow B., Minne H.W. Effects of a New Spinal Orthosis on Posture, Trunk Strength, and Quality of Life in Women with Postmenopausal Osteoporosis: A Randomized Trial // American Journal of Physical Medicine & Rehabilitation. - 2004. - Vol. 83. - Effects of a New Spinal Orthosis on Posture, Trunk Strength, and Quality of Life in Women with Postmenopausal Osteoporosis. - No. 3. - P. 177-186.

259. Jin Y.Z., Lee J.H. Effect of Brace to Osteoporotic Vertebral Fracture: a Meta-Analysis // Journal of Korean Medical Science. - 2016. - Vol. 31. - Effect of Brace to Osteoporotic Vertebral Fracture. - No. 10. - P. 1641.

260. Valentin G.H., Pedersen L.N., Maribo T. Wearing an active spinal orthosis improves back extensor strength in women with osteoporotic vertebral fractures // Prosthetics & Orthotics International. - 2014. - Vol. 38. - No. 3. - P. 232-238.

261. Matussek J., Boluki D., , Grifka J. Orthesenversorgung bei Osteoporose und osteoporotischen // Der . - 2010. - Vol. 39. - No. 4. - P. 387-396.

262. Shariatzadeh H., Modaghegh B.S., Mirzaei A. The Effect of Dynamic Hyperextension Brace on Osteoporosis and Hyperkyphosis Reduction in Postmenopausal Osteoporotic Women // The Archives of Bone and Joint Surgery. - 2017. - Vol. 5. - No. 3. - P. 181-185.

263. Eldemir K., Eldemir S., Ozkul C., Guclu-Gunduz A. The immediate efficacy of the spinomed orthosis and biofeedback posture orthosis on balance and gait in older people with thoracic hyperkyphosis // Gait & Posture. - 2024. - Vol. 111. - P. 136-142.

264. Pfeifer M., Kohlwey L., Begerow B., Minne H.W. Effects of Two Newly Developed Spinal Orthoses on Trunk Muscle Strength, Posture, and Quality-of-Life in Women with Postmenopausal Osteoporosis: A Randomized Trial // American Journal of Physical Medicine & Rehabilitation. - 2011. - Vol. 90. - Effects of Two Newly Developed Spinal Orthoses on Trunk Muscle Strength, Posture, and Quality-of-Life in Women with Postmenopausal Osteoporosis. - No. 10. - P. 805-815.

265. Snow-Harter C., Bouxsein M.L., Lewis B.T., Carter D.R., Marcus R. Effects of resistance and endurance exercise on bone mineral status of young women: A randomized exercise intervention trial // Journal of Bone and Mineral Research. - 1992. - Vol. 7. - Effects of resistance and endurance exercise on bone mineral status of young women. - No. 7. - P. 761-769.

266. Vainionp A., Korpelainen R., Leppluoto J., Jms T. Effects of high-impact exercise on bone mineral density: a randomized controlled trial in premenopausal women // Osteoporosis International. - 2005. - Vol. 16. - Effects of high-impact exercise on bone mineral density. - No. 2. - P. 191-197.

267. Lu X., Wei J., Liu Y., Lu Y. Effects of exercise on bone mineral density in middle-aged and older men: A comprehensive meta-analysis // Archives of Osteoporosis. - 2023. - Vol. 18. - Effects of exercise on bone mineral density in middle-aged and older men. - No. 1. - P. 108.

268. Yu H.-S., Kim J.-J., Kim H.-W., Lewis M.P., Wall I. Impact of mechanical stretch on the cell behaviors of bone and surrounding tissues // Journal of Tissue Engineering. - 2016. - Vol. 7. - P. 2041731415618342.

269. Kelley G.A., Kelley K.S., Tran Z.V. Exercise and Lumbar Spine Bone Mineral Density in Postmenopausal Women: A Meta-Analysis of Individual Patient Data // The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. - 2002. - Vol. 57. - Exercise and Lumbar Spine Bone Mineral Density in Postmenopausal Women. - No. 9. - P. M599-M604.

270. Lee J.H., Yun I., Nam C.-M., Jang S.-Y., Park E.-C. Association between physical activity and health-related quality of life in middle-aged and elderly individuals with musculoskeletal disorders: Findings from a national cross-sectional study in Korea // PLOS ONE. - 2023. - Vol. 18. - Association between physical activity and health-related quality of life in middle-aged and elderly individuals with musculoskeletal disorders. - No. 11. - P. e0294602.

271. Michael Y.L., Whitlock E.P., Lin J.S., Fu R., O'Connor E.A., Gold R. Primary Care-Relevant Interventions to Prevent Falling in Older Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force // Annals of Internal Medicine. - 2010. - Vol. 153. - Primary Care-Relevant Interventions to Prevent Falling in Older Adults. - No. 12. - P. 815-825.

272. Howe T.E., Shea B., Dawson L.J., Downie F., Murray A., Ross C., Harbour R.T., Caldwell L.M., Creed G. Exercise for preventing and treating osteoporosis in postmenopausal women // Cochrane Database of Systematic Reviews. - 2011.

273. Sherrington C., Whitney J.C., Lord S.R., Herbert R.D., Cumming R.G., Close J.C.T. Effective Exercise for the Prevention of Falls: A Systematic Review and Meta-Analysis // Journal of the American Geriatrics Society. - 2008. - Vol. 56. - Effective Exercise for the Prevention of Falls. - No. 12. - P. 2234-2243.

274. Howe T.E., Rochester L., Neil F., Skelton D.A., Ballinger C. Exercise for improving balance in older people // Cochrane Database of Systematic Reviews. - 2011. - Vol. 2012. - No. 5.

275. Li W.-C., Chen Y.-C., Yang R.-S., Tsauo J.-Y. Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: a systematic review and meta-analysis // Clinical Rehabilitation. - 2009. - Vol. 23. - Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women. - No. 10. - P. 888-896.

276. , Carroll Bone Mineral Density in Adults Disabled Through Acquired Neurological Conditions: A Review // Journal of Clinical Densitometry. - 2011. - Vol. 14. - Bone Mineral Density in Adults Disabled Through Acquired Neurological Conditions. - No. 2. - P. 85-94.

277. Dawson-Hughes B., Mithal A., Bonjour J.-P., Boonen S., Burckhardt P., Fuleihan G.E.-H., Josse R.G., Lips P., Morales-Torres J., Yoshimura N. IOF position statement: vitamin D recommendations for older adults // Osteoporosis International. - 2010. - Vol. 21. - IOF position statement. - No. 7. - P. 1151-1154.

278. The DIPART (vitamin D Individual Patient Analysis of Randomized Trials) Group Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe // BMJ. - 2010. - Vol. 340. - No. jan12 1. - P. b5463-b5463.

279. Tripkovic L., Lambert H., Hart K., Smith C.P., Bucca G., Penson S., Chope G., , Berry J., Vieth R., Lanham-New S. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis // The American Journal of Clinical Nutrition. - 2012. - Vol. 95. - Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status. - No. 6. - P. 1357-1364.

280. Hassan AB, Hozayen RF, Alotaibi RA, Tayem YI. Therapeutic and maintenance regimens of vitamin D3 supplementation in healthy adults: A systematic review. Cell Mol Biol (Noisy-le-grand). 2018;64(14):8-14.

281. Kearns M.D., Alvarez J.A., Tangpricha V. Large, Single-Dose, Oral Vitamin D Supplementation in Adult Populations: A Systematic Review // Endocrine Practice. - 2014. - Vol. 20. - Large, Single-Dose, Oral Vitamin D Supplementation in Adult Populations. - No. 4. - P. 341-351.

282. Tabatabaeizadeh S., Avan A., Bahrami A., Khodashenas E., Esmaeili H., Ferns G.A., Abdizadeh M.F., Ghayour-Mobarhan M. High Dose Supplementation of Vitamin D Affects Measures of Systemic Inflammation: Reductions in High Sensitivity C-Reactive Protein Level and Neutrophil to Lymphocyte Ratio (NLR) Distribution // Journal of Cellular Biochemistry. - 2017. - Vol. 118. - High Dose Supplementation of Vitamin D Affects Measures of Systemic Inflammation. - No. 12. - P. 4317-4322.

283. Esfandiari A., Pourghassem Gargari B., Noshad H., Sarbakhsh P., Mobasseri M., Barzegari M., Arzhang P. The effects of vitamin D3 supplementation on some metabolic and inflammatory markers in diabetic nephropathy patients with marginal status of vitamin D: A randomized double blind placebo controlled clinical trial // Diabetes & Metabolic Syndrome: Clinical Research & Reviews. - 2019. - Vol. 13. - The effects of vitamin D3 supplementation on some metabolic and inflammatory markers in diabetic nephropathy patients with marginal status of vitamin D. - No. 1. - P. 278-283.

284. Dalle Carbonare L., Valenti M.T., Del Forno F., Piacentini G., Pietrobelli A. Vitamin D Daily versus Monthly Administration: Bone Turnover and Adipose Tissue Influences // Nutrients. - 2018. - Vol. 10. - Vitamin D Daily versus Monthly Administration. - No. 12. - P. 1934.

285. Yogeswari Venugopal, Sharifah F Wan Muhamad Hatta, MRCP, Nurbazlin Musa, Siti Abdul Rahman, Jeyakantha Ratnasingam, Sharmila Sunita Paramasivam, Lee Ling Lim, Luqman Ibrahim, Karen Choong, Alexander TB Tan, et al. Maintenance vitamin D3 dosage requirements in Chinese women with post menopausal osteoporosis living in the tropics. Asia Pacific Journal of Clinical Nutrition 2017; 26(3). doi: 10.6133/apjcn.042016.10.

286. Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е., Дзеранова Л.К., Каронова Т.Л., Ильин А.В., Мельниченко Г.А., Дедов И.И. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы Эндокринологии. 2016;62(4):60-84. https://doi.org/10.14341/probl201662460-84.

287. Heaney R.P., Davies K.M., Chen T.C., Holick M.F., Barger-Lux M.J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol // The American Journal of Clinical Nutrition. - 2003. - Vol. 77. - No. 1. - P. 204-210.

288. Broe K.E., Chen T.C., Weinberg J., Bischoff-Ferrari H.A., Holick M.F., Kiel D.P. A Higher Dose of Vitamin D Reduces the Risk of Falls in Nursing Home Residents: A Randomized, Multiple-Dose Study // Journal of the American Geriatrics Society. - 2007. - Vol. 55. - A Higher Dose of Vitamin D Reduces the Risk of Falls in Nursing Home Residents. - No. 2. - P. 234-239.

289. Dietary Reference Intakes for Calcium and Vitamin D. Washington, D.C.: National Academies Press; 2011. p. 13050.

290. Smith L.M., Gallagher J.C., Suiter C. Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial // The Journal of Steroid Biochemistry and Molecular Biology. - 2017. - Vol. 173. - Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls. - P. 317-322.

291. Pludowski P., Takacs I., Boyanov M., Belaya Z., Diaconu C.C., Mokhort T., Zherdova N., Rasa I., Payer J., Pilz S. Clinical Practice in the Prevention, Diagnosis and Treatment of Vitamin D Deficiency: A Central and Eastern European Expert Consensus Statement // Nutrients. - 2022. - Vol. 14. - Clinical Practice in the Prevention, Diagnosis and Treatment of Vitamin D Deficiency. - No. 7. - P. 1483.

292. Ginde A.A., Blatchford P., Breese K., Zarrabi L., Linnebur S.A., Wallace J.I., Schwartz R.S. High-Dose Monthly Vitamin D for Prevention of Acute Respiratory Infection in Older Long-Term Care Residents: A Randomized Clinical Trial // Journal of the American Geriatrics Society. - 2017. - Vol. 65. - High-Dose Monthly Vitamin D for Prevention of Acute Respiratory Infection in Older Long-Term Care Residents. - No. 3. - P. 496-503.

293. Химический состав пищевых продуктов, используемых в Российской Федерации доступен по ссылке: http://web.ion.ru.

294. Boonen S., Bischoff-Ferrari H.A., Cooper C., Lips P., Ljunggren O., Meunier P.J., Reginster J.-Y. Addressing the Musculoskeletal Components of Fracture Risk with Calcium and Vitamin D: A Review of the Evidence // Calcified Tissue International. - 2006. - Vol. 78. - Addressing the Musculoskeletal Components of Fracture Risk with Calcium and Vitamin D. - No. 5. - P. 257-270.

295. Tang B.M., Eslick G.D., Nowson C., Smith C., Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis // The Lancet. - 2007. - Vol. 370. - Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older. - No. 9588. - P. 657-666.

296. Richy F., Dukas L., Schacht E. Differential Effects of D-Hormone Analogs and Native Vitamin D on the Risk of Falls: A Comparative Meta-Analysis // Calcified Tissue International. - 2008. - Vol. 82. - Differential Effects of D-Hormone Analogs and Native Vitamin D on the Risk of Falls. - No. 2. - P. 102-107.

297. Del Valle E., Negri A.L., Fradinger E., Canalis M., Bevione P., Curcelegui M., Bravo M., Puddu M., Marini A., Ryba J., Peri P., Rosa Diez G., Sintado L., Gottlieb E. Weekly high-dose ergocalciferol to correct vitamin D deficiency/insufficiency in hemodialysis patients: A pilot trial // Hemodialysis International. - 2015. - Vol. 19. - Weekly high-dose ergocalciferol to correct vitamin <span style="font-variant. - No. 1. - P. 60-65.

298. Mager D.R., Jackson S.T., Hoffmann M.R., Jindal K., Senior P.A. "Vitamin D supplementation and bone health in adults with diabetic nephropathy: the protocol for a randomized controlled trial" // BMC Endocrine Disorders. - 2014. - Vol. 14. - "Vitamin D supplementation and bone health in adults with diabetic nephropathy. - No. 1. - P. 66.

299. Baber R.J., Panay N., Fenton A. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy // Climacteric. - 2016. - Vol. 19. - No. 2. - P. 109-150.

300. Writing Group For The Women's Health Initiative Investigators Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial // JAMA: The Journal of the American Medical Association. - 2002. - Vol. 288. - Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. - No. 3. - P. 321-333.

301. Ettinger B., Ensrud K.E., Wallace R., Johnson K.C., Cummings S.R., Yankov V., Vittinghoff E., Grady D. Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial: // Obstetrics & Gynecology. - 2004. - Vol. 104. - Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density. - No. 3. - P. 443-451.

302. De Villiers T.J., Hall J.E., Pinkerton J.V., , Rees M., Yang C., Pierroz D.D. Revised global consensus statement on menopausal hormone therapy // Maturitas. - 2016. - Vol. 91. - P. 153-155.

303. McLellan AR, Reid DM, Forbes K, Reid R, Campbell C, Gregori A, Raby N, Simpson A. Effectiveness of strategies for the secondary prevention of osteoporotic fractures in Scotland (CEPS 99/03). Glasgow (UK): NHS Quality Improvement Scotland; 2004.

304. IOF Fracture Working Group, , Marsh D., Mitchell P.J., McLellan A.R., Stenmark J., Pierroz D.D., Kyer C., Cooper C. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle // Osteoporosis International. - 2013. - Vol. 24. - Capture the Fracture. - No. 8. - P. 2135-2152.

305. Hagino H., Sawaguchi T., Endo N., Ito Y., Nakano T., Watanabe Y. The Risk of a Second Hip Fracture in Patients after Their First Hip Fracture // Calcified Tissue International. - 2012. - Vol. 90. - No. 1. - P. 14-21.

306. Dell R. Fracture prevention in Kaiser Permanente Southern California // Osteoporosis International. - 2011. - Vol. 22. - No. S3. - P. 457-460.

307. Nakayama A., Major G., Holliday E., Attia J., Bogduk N. Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate // Osteoporosis International. - 2016. - Vol. 27. - No. 3. - P. 873-879.

308. IOF CSA Fracture Working Group, Marsh D., , Beaton D.E., Bogoch E.R., Boonen S., Brandi M.-L., McLellan A.R., Mitchell P.J., Sale J.E.M., Wahl D.A. Coordinator-based systems for secondary prevention in fragility fracture patients // Osteoporosis International. - 2011. - Vol. 22. - No. 7. - P. 2051-2065.

309. Front Matter // Secondary Fracture Prevention. - Elsevier, 2019. - P. iii.

310. Ganda K., Puech M., Chen J.S., Speerin R., Bleasel J., Center J.R., Eisman J.A., March L., Seibel M.J. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis // Osteoporosis International. - 2013. - Vol. 24. - Models of care for the secondary prevention of osteoporotic fractures. - No. 2. - P. 393-406.

311. Huntjens K.M.B., Van Geel T.A.C.M., Van Den Bergh J.P.W., Van Helden S., Willems P., Winkens B., Eisman J.A., Geusens P.P., Brink P.R.G. Fracture Liaison Service: Impact on Subsequent Nonvertebral Fracture Incidence and Mortality // Journal of Bone and Joint Surgery. - 2014. - Vol. 96. - Fracture Liaison Service. - No. 4. - P. e29.

312. Hawley S., Javaid M.K., Prieto-Alhambra D., Lippett J., Sheard S., Arden N.K., Cooper C., Judge A. Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study // Age and Ageing. - 2016. - Vol. 45. - Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients. - No. 2. - P. 236-242.

313. Majumdar S.R., Lier D.A., Rowe B.H., Russell A.S., McAlister F.A., Maksymowych W.P., Hanley D.A., Morrish D.W., Johnson J.A. Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture // Osteoporosis International. - 2011. - Vol. 22. - No. 6. - P. 1799-1808.

314. McLellan A.R., Wolowacz S.E., Zimovetz E.A., Beard S.M., Lock S., McCrink L., Adekunle F., Roberts D. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision // Osteoporosis International. - 2011. - Vol. 22. - Fracture liaison services for the evaluation and management of patients with osteoporotic fracture. - No. 7. - P. 2083-2098.

315. Li N., Hiligsmann M., Boonen A., Van Oostwaard M.M., De Bot R.T.A.L., Wyers C.E., Bours S.P.G., Van Den Bergh J.P. The impact of fracture liaison services on subsequent fractures and mortality: a systematic literature review and meta-analysis // Osteoporosis International. - 2021. - Vol. 32. - The impact of fracture liaison services on subsequent fractures and mortality. - No. 8. - P. 1517-1530.

316. Wu C.-H., Tu S.-T., Chang Y.-F., Chan D.-C., Chien J.-T., Lin C.-H., Singh S., Dasari M., Chen J.-F., Tsai K.-S. Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: A systematic literature review and meta-analysis // Bone. - 2018. - Vol. 111. - Fracture liaison services improve outcomes of patients with osteoporosis-related fractures. - P. 92-100.

317. Wu M.-H., Lin Y.-S., Wu C., Lee C.-Y., Chen Y.-C., Huang T.-J., Cheng J.-S. Timing of Bisphosphonate (Alendronate) Initiation after Surgery for Fragility Fracture: A Population-Based Cohort Study // Journal of Clinical Medicine. - 2021. - Vol. 10. - Timing of Bisphosphonate (Alendronate) Initiation after Surgery for Fragility Fracture. - No. 12. - P. 2541.

318. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., Cannata J., Balogh A., Lemmel E.-M., Pors-Nielsen S., Rizzoli R., Genant H.K., Reginster J.-Y. The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis // New England Journal of Medicine. - 2004. - Vol. 350. - No. 5. - P. 459-468.

319. Reginster J.Y., Seeman E., De Vernejoul M.C., Adami S., Compston J., Phenekos C., Devogelaer J.P., Curiel M.D., Sawicki A., Goemaere S., Sorensen O.H., Felsenberg D., Meunier P.J. Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study // The Journal of Clinical Endocrinology & Metabolism. - 2005. - Vol. 90. - Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis. - No. 5. - P. 2816-2822.

320. Thompson K., Rogers M.J., Coxon F.P., Crockett J.C. Cytosolic Entry of Bisphosphonate Drugs Requires Acidification of Vesicles after Fluid-Phase Endocytosis // Molecular Pharmacology. - 2006. - Vol. 69. - No. 5. - P. 1624-1632.

321. Dunford J.E., Rogers M.J., Ebetino F.H., Phipps R.J., Coxon F.P. Inhibition of Protein Prenylation by Bisphosphonates Causes Sustained Activation of Rac, Cdc42, and Rho GTPases // Journal of Bone and Mineral Research. - 2006. - Vol. 21. - No. 5. - P. 684-694.

322. U.S. Food and Drug Administration. Reclast (zoledronic acid): Drug Safety Communication - New Contraindication and Updated Warning on Kidney Impairment. Posted 09/01/2011. Доступно по http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm270464.htm.

323. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., Gagel R.F., Gilsanz V., Guise T., Koka S., McCauley L.K., McGowan J., McKee M.D., Mohla S., Pendrys D.G., Raisz L.G., Ruggiero S.L., Shafer D.M., Shum L., Silverman S.L., Van Poznak C.H., Watts N., Woo S.-B., Shane E. Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research // Journal of Bone and Mineral Research. - 2007. - Vol. 22. - Bisphosphonate-Associated Osteonecrosis of the Jaw. - No. 10. - P. 1479-1491.

324. Marie P.J. Signaling Pathways Affecting Skeletal Health // Current Osteoporosis Reports. - 2012. - Vol. 10. - No. 3. - P. 190-198.

325. Tashjian A.H., Chabner B.A. Commentary on Clinical Safety of Recombinant Human Parathyroid Hormone 1-34 in the Treatment of Osteoporosis in Men and Postmenopausal Women // Journal of Bone and Mineral Research. - 2002. - Vol. 17. - No. 7. - P. 1151-1161.

326. Vahle J.L., Sato M., Long G.G., Young J.K., Francis P.C., Engelhardt J.A., Westmore M.S., Ma Y.L., Nold J.B. Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety // Toxicologic Pathology. - 2002. - Vol. 30. - No. 3. - P. 312-321.

327. Miller P.D., Schwartz E.N., Chen P., Misurski D.A., Krege J.H. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment // Osteoporosis International. - 2007.a - Vol. 18. - No. 1. - P. 59-68.

328. Nielsen S.P., Slosman D., , Basse-Cathalinat B., De Cassin P., Roux C., Meunier P.J. Influence of Strontium on Bone Mineral Density and Bone Mineral Content Measurements by Dual X-Ray Absorptiometry // Journal of Clinical Densitometry. - 1999. - Vol. 2. - No. 4. - P. 371-379.

329. Recker R.R., Marin F., Ish-Shalom S., , Hawkins F., Kapetanos G., De La , Kekow J., Farrerons J., Sanz B., Oertel H., Stepan J. Comparative Effects of Teriparatide and Strontium Ranelate on Bone Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal Women With Osteoporosis // Journal of Bone and Mineral Research. - 2009. - Vol. 24. - No. 8. - P. 1358-1368.